Survival expectation after thrombosis and overt-myelofibrosis in essential thrombocythemia and prefibrotic myelofibrosis: a multistate model approach

Affiliations

• ¹ FROM Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy.
• ² Center Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Department of Experimental and Clinical Medicine, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy.
• ³ Department of Molecular Medicine, University of Pavia, Pavia, Italy.
• ⁴ Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy.
• ⁵ Institute of Hematology, Catholic University, Rome, Italy.
• ⁶ Fondazione Policlinico 'A. Gemelli'' IRCCS, Rome, Italy.
• ⁷ Hematology and Bone Marrow Transplant Unit, ASST Papa Giovanni XXIII, Bergamo, Italy.
• ⁸ Department of Oncology and Hematology, University of Milan, Milan, Italy.
• ⁹ Division of Hematology, ''S. Bortolo'' Hospital, Vicenza, Italy.
• ¹⁰ Department of Medicine - DIMED, University of Padova, Padova, Italy.
• ¹¹ Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.
• ¹² Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
• ¹³ Institute of Pathology, University of Cologne, Cologne, Germany.
• ¹⁴ Hematology Division, Mayo Clinic, Rochester, MN, USA.
• ¹⁵ FROM Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy. tbarbui@fondazionefrom.it.